lubiprostone

Lubiprostone (referred to as 'rupiprostone' in some clinical trial registries such as ChiCTR2400083154) is a bicyclic fatty acid derived from prostaglandin E1 that acts as a selective activator of type 2 chloride channels (ClC-2) in the apical membrane of the intestinal epithelium. By stimulating the secretion of chloride-rich intestinal fluid into the lumen, it enhances gastrointestinal motility and improves stool consistency without significantly altering serum electrolyte levels. It was originally developed by Sucampo Pharmaceuticals (later acquired by Mallinckrodt) and is marketed for the treatment of chronic idiopathic constipation, opioid-induced constipation, and irritable bowel syndrome with constipation (IBS-C). Recent clinical research, including trials sponsored by Binzhou Medical University Hospital, has evaluated its efficacy and safety specifically in patients with diabetic constipation.

Brand names

Amitiza

Other names

lubiprostonerupiprostone